The dual Syk/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

PURPOSE: B-cell receptor (BCR)-associated kinase inhibitors such as ibrutinib have revolutionised the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative and resistance is already emerging in a proportion of patients. Interleukin-4 (IL-4), expressed in CLL lymph n...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Cancer Res
Κύριοι συγγραφείς: Blunt, Matthew D, Koehrer, Stefan, Dobson, Rachel, Larrayoz, Marta, Wilmore, Sarah, Hayman, Alice, Parnell, Jack, Smith, Lindsay, Davies, Andrew, Johnson, Peter W, Conley, Pamela B, Pandey, Anjali, Strefford, Jon C, Stevenson, Freda K, Packham, Graham, Forconi, Francesco, Coffey, Greg, Burger, Jan A, Steele, Andrew J
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2016
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5417366/
https://ncbi.nlm.nih.gov/pubmed/27697994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1662
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια